Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines

被引:3
作者
Pillsbury, Alexis [1 ,2 ]
Phillips, Anastasia [1 ]
Deng, Lucy [1 ,2 ]
Quinn, Helen [1 ,2 ]
Macartney, Kristine [1 ,2 ]
Gidding, Heather [1 ,3 ,4 ,5 ]
机构
[1] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia
[2] Univ Sydney, Childrens Hosp Westmead, Clin Sch, Westmead, NSW, Australia
[3] Univ Sydney, Northern Clin Sch, St Leonards, NSW, Australia
[4] Northern Sydney Local Hlth Dist, Kolling Inst, Women & Babies Res, St Leonards, NSW, Australia
[5] Univ NSW, UNSW Med, Sch Populat Hlth, Sydney, NSW, Australia
关键词
COVID-19; vaccination; Vaccine safety; Adverse events; Background rates; GUILLAIN-BARRE-SYNDROME; VEIN-THROMBOSIS; IMMUNIZATION; VACCINATION; MYOCARDITIS; AUSTRALIA; US;
D O I
10.1016/j.vaccine.2023.04.041
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Determining background rates of medical conditions identified as adverse events of special interest (AESI) that may occur following COVID-19 vaccination is important for contextualising and investigating potential vaccine safety signals.Methods: We conducted a retrospective population-based cohort study using linked emergency depart-ment, hospitalisation and death data for 2017 and 2018 from Australia's most populous state, New South Wales. Incident cases of select neurological conditions, arterial or venous thromboembolic conditions, secondary thrombocytopenia, myocarditis/pericarditis, and unique events of anaphylaxis and generalised convulsions were identified using internationally agreed upon diagnostic (ICD-10) codes. State-specific rates per 100,000 person-years were calculated, with further stratification by age group and sex where clinically relevant to the condition, and the number of expected cases nationally in one and 6 weeks was estimated.Results: Background rates of selected neurological conditions were low with the exception of generalised convulsions for which 1,599-1,872 cases were estimated nationally in a 1-week period in the absence of vaccination. Using a narrow case definition, rates of Guillain-Barre Syndrome (3.9 per 100,000 person -years) were higher than international rates reported elsewhere. Thromboembolic and cerebral venous sinus thrombosis event rates increased with age. Myocarditis occurred more commonly in males, and was highest in males aged 18-24 years, with an estimated 1-4 cases expected nationally in a 1-week per-iod.Conclusions: Using routinely collected linked healthcare data provides localised estimates of background rates of new onset or periodic AESI which enables rapid estimation of observed-versus-expected rates of events reported following COVID-19 vaccination. This Australian-specific analysis contributes AESI back-ground rates which can be compared with those from other countries to enhance understanding of geo-graphic variability in the frequency of specific AESI in the absence of vaccination, and can be utilised for signal detection during program implementation.(c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3422 / 3428
页数:7
相关论文
共 52 条
  • [1] Expected Rates of Select Adverse Events After Immunization for Coronavirus Disease 2019 Vaccine Safety Monitoring
    Abara, Winston E.
    Gee, Julianne
    Delorey, Mark
    Tun, Ye
    Mu, Yi
    Shay, David K.
    Shimabukuro, Tom
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (09) : 1569 - 1574
  • [2] Abraham N, 2022, VACCINE
  • [3] Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome
    Ageno, Walter
    Dentali, Francesco
    Pomero, Fulvio
    Fenoglio, Luigi
    Squizzato, Alessandro
    Pagani, Giovanni
    Re, Roberta
    Bonzini, Matteo
    [J]. THROMBOSIS AND HAEMOSTASIS, 2017, 117 (04) : 794 - 800
  • [4] Australian Bureau of Statistics, 2022, TABL 59 EST RES POP
  • [5] Australian Bureau of Statistics, 2022, TABL 5 1 EST RES POP
  • [6] Australian Bureau of Statistics (ABS), 2022, REG POP AG SEX
  • [7] Australian Government Department of Health, COVID 19 VACC ROL UP
  • [8] Australian Government Department of Health, 2022, APPR COVID 19 VACC 2
  • [9] Australian Government Department of Health, COVID-19 Vaccine Weekly Safety Report
  • [10] Australian Government Department of Health and Aged Care, 2023, VAXZ ASTRAZENECA VAC